StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.96+4.67 (+9.88%)

Close on Nov 18, 2026Market cap $1.55BP/E –Yield –

GeneDx operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

GeneDx's operating cash flow for the twelve months ending Jun 30, 2026 was -$48.71M, down 474.0% year over year. For fiscal 2025 it was $33.28M. The highest annual figure on record is $33.28M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$33.28M–
FY2024Dec 31, 2024-$28.50M–
FY2023Dec 31, 2023-$180.15M–
FY2022Dec 31, 2022-$319.16M–
FY2021Dec 31, 2021-$190.43M–
FY2020Dec 31, 2020-$93.13M–
FY2019Dec 31, 2019-$18.73M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.98M-378.1%
Q1 FY2026Mar 31, 2026-$32.41M-418.3%
Q4 FY2025Dec 31, 2025-$3.09M–
Q3 FY2025Sep 30, 2025$15.77M–
Q2 FY2025Jun 30, 2025$10.42M–
Q1 FY2025Mar 31, 2025$10.18M–
Q4 FY2024Dec 31, 2024-$3.18M–
Q3 FY2024Sep 30, 2024-$4.40M–
Q2 FY2024Jun 30, 2024-$4.51M–
Q1 FY2024Mar 31, 2024-$16.41M–
Q4 FY2023Dec 31, 2023-$29.86M–
Q3 FY2023Sep 30, 2023-$41.23M–
Q2 FY2023Jun 30, 2023-$53.50M–
Q1 FY2023Mar 31, 2023-$55.56M–
Q4 FY2022Dec 31, 2022-$64.65M–
Q3 FY2022Sep 30, 2022-$88.36M–
Q2 FY2022Jun 30, 2022-$84.65M–
Q1 FY2022Mar 31, 2022-$81.49M–
Q4 FY2021Dec 31, 2021-$51.99M–
Q3 FY2021Sep 30, 2021-$70.94M–
Q2 FY2021Jun 30, 2021-$25.30M–
Q1 FY2021Mar 31, 2021-$42.21M–
Q4 FY2020Dec 31, 2020-$18.33M–
Q3 FY2020Sep 30, 2020-$365.81K–

More GeneDx figures

See a number that looks wrong?